8-K: Haemonetics Raises FY26 Guidance on Strong Q2 Performance

Haemonetics Corporation reported strong second-quarter fiscal 2026 results, raising its full-year guidance for revenue and adjusted earnings per diluted share, driven by profitable growth and disciplined execution.

Summary

• Second quarter fiscal 2026 revenue was $327.3 million, a 5.3% decrease compared to the prior year, while year-to-date fiscal 2026 revenue was $648.7 million, a 4.8% decrease.
• Organic ex-CSL revenue increased 9.4% in the second quarter and 11.1% year-to-date, indicating strong underlying business performance excluding specific portfolio transitions.
• GAAP earnings per diluted share for Q2 FY26 increased to $0.81 from $0.66 in Q2 FY25, a 22.9% rise.
• Adjusted earnings per diluted share for Q2 FY26 increased to $1.27 from $1.12 in Q2 FY25, a 13.4% rise.
• Cash flow from operating activities for Q2 FY26 was $111.3 million, a 128.0% increase, and free cash flow was $88.7 million, a 139.6% increase.
• Gross margin improved to 59.5% (GAAP) and 60.5% (Adjusted) in Q2 FY26, driven by Plasma share gains, product mix, pricing benefits, and decreased restructuring costs.
• Operating income increased 13.1% to $58.5 million (GAAP) and adjusted operating income increased 4.5% to $87.3 million.
• The company repurchased 1,430,579 shares of its common stock for $75.0 million during the second quarter of fiscal 2026 as part of its $500.0 million share repurchase program.
• Haemonetics raised its total company fiscal 2026 guidance for reported revenue, organic revenue, organic ex-CSL revenue, adjusted earnings per diluted share, and free cash flow.

Sentiment

Score: 8

Explanation: The company delivered strong financial results, significantly increased cash flow, improved profitability, and raised its full-year guidance across multiple key metrics, indicating robust operational performance and a positive outlook despite some reported revenue declines due to portfolio transitions.

Positives

• GAAP earnings per diluted share increased 22.9% to $0.81 in Q2 FY26 compared to $0.66 in Q2 FY25.
• Adjusted earnings per diluted share increased 13.4% to $1.27 in Q2 FY26 compared to $1.12 in Q2 FY25.
• Cash flow from operating activities surged 128.0% to $111.3 million in Q2 FY26.
• Free cash flow dramatically increased 139.6% to $88.7 million in Q2 FY26.
• Gross margin improved significantly to 59.5% (GAAP) and 60.5% (Adjusted) due to Plasma share gains, product mix, and pricing benefits.
• Organic ex-CSL revenue grew 9.4% in Q2 FY26 and 11.1% year-to-date, demonstrating strong underlying business growth.
• Adjusted operating income increased 4.5% to $87.3 million, with adjusted operating margin expanding by 250 basis points to 26.7%.
• Fiscal 2026 guidance was raised for total company reported revenue, organic revenue, organic ex-CSL revenue, adjusted earnings per diluted share (to $4.80-$5.00 from $4.70-$5.00), and free cash flow (to $170M-$210M from $160M-$200M).
• The company's strong balance sheet supports additional value creation avenues, including growth initiatives, debt repayment, and share buybacks.

Negatives

• Reported total net revenue decreased 5.3% in Q2 FY26 to $327.3 million and 4.8% year-to-date to $648.7 million.
• Plasma business unit reported a 9.5% revenue decrease and a 10.1% organic revenue decrease in Q2 FY26.
• Blood Center revenue decreased 17.6% reported in Q2 FY26 and 19.6% year-to-date, primarily due to the divestiture of the Whole Blood product line and exit of certain liquid solution products.
• Interventional Technologies revenue decreased 4.6% reported and 5.0% organic in Q2 FY26, with management noting targeted actions are underway to strengthen commercial execution.
• Impairment charges of intangible assets contributed to the increase in GAAP operating expenses.

Risks

• Availability and demand for the company's products.
• Ability to successfully develop and market new products and technologies.
• Impact of competitive products and pricing.
• Product quality issues.
• Disruptions caused by cybersecurity events.
• Any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures.
• Pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• The company's ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative.
• The effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures.
• Regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions.
• Indebtedness incurred by the company, including the conditional conversion feature of its convertible notes.
• The company's ability to protect its intellectual property.
• Litigation.
• The impact of share repurchases on the company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase programs' effectiveness.

Future Outlook

Haemonetics raised its fiscal 2026 guidance for total company reported revenue to a decrease of 1-4% (from a previous decrease of 3-6%), organic revenue to a decrease of 1-2% (from a previous decrease of 2-1%), and organic ex-CSL revenue to an increase of 7-10% (from a previous increase of 6-9%). The company also raised its adjusted earnings per diluted share guidance to $4.80-$5.00 (from $4.70-$5.00) and free cash flow guidance to $170M-$210M (from $160M-$200M), while reaffirming adjusted operating margin guidance of 26-27%.

Management Comments

• "Our second quarter results demonstrate disciplined execution and increasingly profitable growth across our business—growing cash flow, earnings and operating income while absorbing the impact from last year's portfolio transitions."
• "With the majority of our businesses outperforming and targeted actions underway to strengthen commercial execution in Interventional Technologies, we are firmly on track to deliver our updated fiscal year 2026 guidance and long-range plan objectives."
• "Our strong balance sheet will enable additional avenues for value creation, including advancing growth initiatives, debt repayment, and share buybacks."

Industry Context

The medical technology sector, particularly in blood and plasma management, continues to see demand for innovative solutions. Haemonetics' focus on Plasma share gains and strong performance in Hospital technologies (Blood Management Technologies growing 12.2% organic ex-CSL) aligns with broader industry trends towards optimizing healthcare efficiency and patient outcomes. The strategic divestiture of the Whole Blood product line reflects a common practice of portfolio rationalization in dynamic med-tech markets. Challenges in Interventional Technologies suggest specific competitive pressures or market shifts within that segment, which the company is addressing with targeted commercial execution actions.

Stakeholder Impact

• Shareholders: Positive impact due to increased earnings, raised guidance, ongoing share repurchase program, and potential for further value creation through growth initiatives and debt repayment.
• Employees: Potential for increased investment in research and development and growth initiatives, balanced with disciplined cost management across general and administrative functions.
• Customers: Continued focus on innovative solutions and improving healthcare quality, effectiveness, and efficiency.
• Creditors: Positive impact from strong cash flow generation and debt repayment initiatives.

Next Steps

• Host a conference call with investors and analysts on Thursday, November 6, 2025, at 8:00 a.m. ET to discuss second quarter fiscal 2026 results.
• Continue to advance growth initiatives, debt repayment, and share buybacks.
• Strengthen commercial execution in Interventional Technologies.
• Deliver updated fiscal year 2026 guidance and long-range plan objectives.

Key Dates

Recommendation

The company demonstrated strong operational execution with significant increases in profitability and cash flow, even while absorbing impacts from portfolio transitions. The upward revision of full-year guidance for revenue, adjusted EPS, and free cash flow signals management's confidence and improved outlook. The ongoing share repurchase program further enhances shareholder value. Despite some reported revenue declines due to strategic divestitures, the underlying organic ex-CSL growth is robust, indicating a healthy core business. The strong balance sheet provides flexibility for future growth and shareholder returns.

Keywords

Haemonetics, HAE, financial results, Q2 2026, fiscal 2026, earnings, revenue, plasma, blood center, hospital technologies, medical technology, cash flow, guidance, share repurchase, operating income, gross margin